Four-Drug attack on hodgkin lymphoma shows promise in early trial
NCT ID NCT05922904
Summary
This study is testing a combination of four drugs (brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine) for people with advanced or bulky Hodgkin lymphoma who haven't had treatment before. Researchers are using PET scans during treatment to see if they can adjust therapy based on how well it's working. The main goal is to see how many patients achieve complete remission and how safe this approach is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.